Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.
Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.
The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments